Vivesto AB
Research Vivesto AB (OMAX) on Bullrun: market cap EUR 33.21K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOMAX
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 33.21K
- Financial periodFY2022
- RevenueSEK 1.02M
- Revenue growth-96.1%
- Net income-SEK 356.72M
- Free cash flow-SEK 80.79M
Valuation Snapshot
latest market cap is EUR 33.21K.
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer.
Frequently asked questions
What is Vivesto AB's market cap?
Vivesto AB's market capitalization is EUR 33.21K.
What does Vivesto AB do?
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma.